| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Natalia Battista, Filomena Fezza, Alessandro Finazzi-Agrò, Mauro Maccarron. The endocannabinoid system in neurodegeneration. The Italian journal of biochemistry. vol 55. issue 3-4. 2007-02-20. PMID:17274532. |
thus, aea and 2-ag mimic several pharmacological effects of the exogenous cannabinoid delta9-tetrahydrocannabinol, the psychoactive principle of hashish and marijuana. |
2007-02-20 |
2023-08-12 |
Not clear |
| Duncan Ryan, Alison J Drysdale, Roger G Pertwee, Bettina Plat. Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. Neuroscience letters. vol 408. issue 3. 2007-01-23. PMID:16997463. |
differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. |
2007-01-23 |
2023-08-12 |
Not clear |
| Duncan Ryan, Alison J Drysdale, Roger G Pertwee, Bettina Plat. Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. Neuroscience letters. vol 408. issue 3. 2007-01-23. PMID:16997463. |
we have shown previously that the plant cannabinoid cannabidiol (cbd) elevates intracellular calcium levels in both cultured hippocampal neurones and glia. |
2007-01-23 |
2023-08-12 |
Not clear |
| A Paradisi, S Oddi, M Maccarron. The endocannabinoid system in ageing: a new target for drug development. Current drug targets. vol 7. issue 11. 2007-01-04. PMID:17100593. |
anandamide (n-arachidonoylethanolamine; aea) and 2-arachidonoylglycerol are the main endogenous agonists of cannabinoid receptors able to mimic several pharmacological effects of delta(9)-tetrahydrocannabinol, the active principle of cannabis sativa preparations like hashish and marijuana. |
2007-01-04 |
2023-08-12 |
human |
| Roger G Pertwe. Cannabinoid pharmacology: the first 66 years. British journal of pharmacology. vol 147 Suppl 1. 2006-12-27. PMID:16402100. |
research into the pharmacology of individual cannabinoids that began in the 1940s, several decades after the presence of a cannabinoid was first detected in cannabis, is concisely reviewed. |
2006-12-27 |
2023-08-12 |
Not clear |
| Mohamed Ben Ama. Cannabinoids in medicine: A review of their therapeutic potential. Journal of ethnopharmacology. vol 105. issue 1-2. 2006-12-22. PMID:16540272. |
the key words used were cannabis, marijuana, marihuana, hashish, hashich, haschich, cannabinoids, tetrahydrocannabinol, thc, dronabinol, nabilone, levonantradol, randomised, randomized, double-blind, simple blind, placebo-controlled, and human. |
2006-12-22 |
2023-08-12 |
human |
| John E Fisk, Catharine Montgomery, Michelle Wareing, Philip N Murph. The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic? Human psychopharmacology. vol 21. issue 6. 2006-12-22. PMID:16915582. |
in recent years evidence has emerged suggesting that cannabinoids, the active ingredients in cannabis, can be neuroprotective under certain conditions. |
2006-12-22 |
2023-08-12 |
Not clear |
| Linda J Kochman, Angela Amancio dos Santos, Casimir A Fornal, Barry L Jacob. Despite strong behavioral disruption, Delta9-tetrahydrocannabinol does not affect cell proliferation in the adult mouse dentate gyrus. Brain research. vol 1113. issue 1. 2006-12-13. PMID:16930565. |
marijuana has been hypothesized to target neurons in the hippocampus because of the abundance of cannabinoid receptors present in this structure. |
2006-12-13 |
2023-08-12 |
mouse |
| Javier Palazuelos, Tania Aguado, Ainara Egia, Raphael Mechoulam, Manuel Guzmán, Ismael Galve-Roper. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 20. issue 13. 2006-11-27. PMID:17015409. |
cannabinoids, the active components of marijuana and their endogenous counterparts, act on the brain and many other organs through the widely expressed cb1 cannabinoid receptor. |
2006-11-27 |
2023-08-12 |
mouse |
| Jordi Pere. Combined cannabinoid therapy via an oromucosal spray. Drugs of today (Barcelona, Spain : 1998). vol 42. issue 8. 2006-11-14. PMID:16969427. |
extensive basic science research has identified the potential therapeutic benefits of active compounds extracted from the cannabis sativa l. plant (the cannabinoids). |
2006-11-14 |
2023-08-12 |
human |
| Jordi Pere. Combined cannabinoid therapy via an oromucosal spray. Drugs of today (Barcelona, Spain : 1998). vol 42. issue 8. 2006-11-14. PMID:16969427. |
gw pharmaceuticals have developed sativex (gw- 1,000-02), a combined cannabinoid medicine that delivers and maintains therapeutic levels of two principal cannabinoids, delta-9-tetrahydrocannabinol (thc) and cannabidiol (cbd), via an oromucosal pump spray, that aims to minimize psychotropic side effects. |
2006-11-14 |
2023-08-12 |
human |
| Charles A Lunn, Eva-Pia Reich, Loretta Bobe. Targeting the CB2 receptor for immune modulation. Expert opinion on therapeutic targets. vol 10. issue 5. 2006-11-14. PMID:16981823. |
with the discovery of a peripheral cannabinoid receptor associated with immune cells, many laboratories have sought to link the immunoregulatory activities of cannabinoid compounds with this receptor, hoping that such compounds would lack the psychoactive effects of marijuana and other nonspecific cannabinoid agonists. |
2006-11-14 |
2023-08-12 |
Not clear |
| S Morgello, C E Holzer, E Ryan, C Young, M Naseer, S A Castellon, A B Frol, J Hampton Atkinson, B B Gelman, I Grant, E J Singe. Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium. International journal of methods in psychiatric research. vol 15. issue 3. 2006-11-09. PMID:17019897. |
overall the prism was reliable in assessing both past and current disorders except for current cannabis disorders when patients had concomitant cannabinoid prescriptions for medical therapy. |
2006-11-09 |
2023-08-12 |
Not clear |
| Tangying Lu, Cathy Newton, Izabella Perkins, Herman Friedman, Thomas W Klei. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. The Journal of pharmacology and experimental therapeutics. vol 319. issue 1. 2006-11-02. PMID:16837556. |
marijuana cannabinoids, such as delta-9-tetrahydrocannabinoid (thc), suppress type 1 t-helper 1 (th1) immunity in a variety of models, including infection with the intracellular pathogen legionella pneumophila (lp). |
2006-11-02 |
2023-08-12 |
mouse |
| Leyre Mestre, Fernando Correa, Fabian Docagne, Diego Clemente, Carmen Guaz. The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochemical pharmacology. vol 72. issue 7. 2006-10-30. PMID:16914119. |
other cannabinoids such as 2-arachidonoyl glycerol (2-ag) or the abnormal cannabidiol (abn-cbd) failed to affect cox-2 in our conditions. |
2006-10-30 |
2023-08-12 |
Not clear |
| Natalya M Kogan, Cristina Blázquez, Luis Alvarez, Ruth Gallily, Michael Schlesinger, Manuel Guzmán, Raphael Mechoula. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Molecular pharmacology. vol 70. issue 1. 2006-10-24. PMID:16571653. |
we have reported that a new cannabinoid anticancer quinone, cannabidiol hydroxyquinone (hu-331), is highly effective against tumor xenografts in nude mice. |
2006-10-24 |
2023-08-12 |
mouse |
| Steven W Paugh, Michael P Cassidy, Hengjun He, Sheldon Milstien, Laura J Sim-Selley, Sarah Spiegel, Dana E Selle. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Molecular pharmacology. vol 70. issue 1. 2006-10-24. PMID:16571654. |
cannabinoid receptors also mediate the effects of delta9-tetrahydrocannabinol, the primary psychoactive ingredient in marijuana, whereas s1p receptors contribute to the immunosuppressant effects of 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (fty720). |
2006-10-24 |
2023-08-12 |
mouse |
| S A Varvel, J L Wiley, R Yang, D T Bridgen, K Long, A H Lichtman, B R Marti. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology. vol 186. issue 2. 2006-10-20. PMID:16572263. |
interactions between thc and cannabidiol in mouse models of cannabinoid activity. |
2006-10-20 |
2023-08-12 |
mouse |
| P Massi, A Vaccani, S Bianchessi, B Costa, P Macchi, D Parolar. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cellular and molecular life sciences : CMLS. vol 63. issue 17. 2006-10-19. PMID:16909207. |
recently, we have shown that the non-psychoactive cannabinoid compound cannabidiol (cbd) induces apoptosis of glioma cells in vitro and tumor regression in vivo. |
2006-10-19 |
2023-08-12 |
human |
| Dai Lu, V Kiran Vemuri, Richard I Duclos, Alexandros Makriyanni. The cannabinergic system as a target for anti-inflammatory therapies. Current topics in medicinal chemistry. vol 6. issue 13. 2006-10-12. PMID:16918457. |
habitual cannabis use has been shown to affect the human immune system, and recent advances in endocannabinoid research provide a basis for understanding these immunomodulatory effects. |
2006-10-12 |
2023-08-12 |
human |